Israel to offer AstraZeneca's Evusheld to immunocompromised people

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York, United States
The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo

JERUSALEM, Feb 15 (Reuters) - Israel will start offering AstraZeneca's (AZN.L) antibody cocktail Evusheld, which is used to prevent COVID-19, to people with compromised immune systems who did not get a sufficient antibody boost from vaccines.

Evusheld has been approved by the U.S. Food and Drug Administration and has proven to be 83% effective in preventing serious illness and death from COVID-19, the Health Ministry said on Tuesday.

It is not a treatment for those already sick or a prevention for those already exposed to the virus, it said.

Evusheld will be made available for people 12 and older who weigh more than 40 kg (88 lb), according to a Health Ministry statement.

It said Evusheld will "be given regardless of past recovery from COVID-19 or receiving previous coronavirus vaccine doses, provided that two weeks have passed since getting the vaccine."

Reporting by Ari Rabinovitch; Editing by Michael Urquhart

Our Standards: The Thomson Reuters Trust Principles.

Read Next